Heartbeam, Inc. · NASDAQ:BEAT
Heartbeam — IPO Roadshow (January 2025)
24 slides from Heartbeam's IPO roadshow presentation, Jan 8, 2025
Slide 1: Total Heart Intelligence… Wherever You Are
Total Heart Intelligence… Wherever You Are NASDAQ: BEAT January 2025
Slide 2: Forward-looking statements
2 This presentation contains forward - looking statements . All statements other than statements of historical fact contained in this presentation, including statements as to the Company’s future results of operations and financial position, planned products and services, business strategy and plans
Slide 3: Introductions
3 Introductions Tim Cruickshank Chief Financial Officer Rob Eno President Rob Eno Chief Executive Officer Richa Gujarati SVP, Product
Slide 4: HeartBeam: Total Heart Intelligence…Wherever You Are
4 HeartBeam: Total Heart Intelligence…Wherever You Are De - risked through recent FDA clearance and near - term milestones Strong commercial plan: Initial target markets validated First ever cable - free 12L ECG for use by patients synthesized from a novel approach that captures heart signals in thr
Slide 5: Today's ECG Technology is Not Adequate
5 CONSUMER - GRADE ECGs • Generally 1 Lead • Not accurate enough • Produce noisy data • Inundate physicians with data • Limited to arrhythmia detection STANDARD 12 Lead ECGs • Current gold standard for data quality and ability to diagnose • Limited to the hospital • Not practical for at - home use •
Slide 6: HeartBeam Overcomes these Limitations, Creating a New Paradigm
6 HeartBeam Overcomes these Limitations, Creating a New Paradigm # OF LEADS 1 LEAD 12 LEADS DESIGN CABLE - FREE, EASY TO USE CABLES/EXTERNAL LEADS 6 LEADS * For Healthcare professional use only 12L ECG with cables Kardia 6L Patch Technology Kardia 1L Kardia 12L* Only Cable - Free 12L ECG 12 - lead s
Slide 7: Fundamental, IP Protected Advances Enable HeartBeam's 12L Technology
7 Fundamental, IP Protected Advances Enable HeartBeam’s 12L Technology IP Breakthrough Credit card - sized device with a novel resistive network captures the “front to back” direction, providing actionable heart intelligence 3 Directions Collects signals in 3 directions , capturing the totality of t
Slide 8: HeartBeam Demo
HeartBeam Demo Heart SBeanr
Slide 9: Strong intellectual property position on core technology and product pipeline
9 Strong intellectual property position on core technology and product pipeline HEARTBEAM 12L SMART WATCH INTEGRATED SYSTEM EXTENDED WEAR PATCH HEARTBEAM 12L ECG SYSTEM Foundational patents granted: synthesis to 12 - lead upon placing band electrodes on chest Multiple patents granted on HeartBeam an
Slide 10: HeartBeam will allow patients with symptoms to get treatment sooner
10 HeartBeam will allow patients with symptoms to get treatment sooner, saving lives and reducing healthcare costs Patients Delay Seeking Care Symptom Onset Arrival at Emergency Room Treatment (stenting) Symptom - to - Door Time Door - to - Balloon Time 3 - 4 hours Variable, Patient denial <90 minut
Slide 11: Significant Body of Evidence on HeartBeam's Groundbreaking Technology
11 PATIENTS IN CLINICAL STUDIES 500+ USERS 250+ RECORDINGS 15,000+ Significant Body of Evidence on HeartBeam’s Groundbreaking Technology Equivalence to 12L for Coronary Occlusions HeartBeam AI + Vector ECG for Complex Arrhythmias Fundamentals of HeartBeam technology HeartBeam algorithm for Heart Att
Slide 12: Large and Rapidly Expanding Body of Evidence
12 Large and Rapidly Expanding Body of Evidence on HeartBeam’s Groundbreaking Technology 12 - lead synthesis software and ischemia product not cleared by the FDA. Not available for sale in the United States and other ge ographies. 1, 5. AHA 2024. 2. Shvilkin, et al, Coronary Artery Occlusion Detecti
Slide 13: HeartBeam Roadmap: Groundbreaking Form Factor and AI Drive Significant Expansion
13 HeartBeam Roadmap: Groundbreaking Form Factor and AI Drive Significant Expansion 12 - lead synthesis software and ischemia product not cleared by the FDA. Not available for sale in the United States and other ge ographies. 31 MILLION US PATIENTS 186 MILLION US PATIENTS 300 MILLION ANNUAL ECGS 1 2
Slide 14: HeartBeam AI: Driving Earlier Insights into Cardiac Conditions
14 HeartBeam AI: Driving Earlier Insights into Cardiac Conditions Transforming data into life - saving insights, predicting cardiac events before they happen 12 - lead synthesis software and ischemia product not cleared by the FDA. Not available for sale in the United States and other ge ographies.
Slide 15: Near-term milestones creating significant momentum
15 Near - term milestones creating significant momentum HeartBeam System Foundational Clearance MI Detection AI Classifications Clinical Commercial Regulatory Initial FDA interactions RAISE - ECG Enrollment Complete FDA Submission Start of Early Access Program FDA Clearance 12L Synthesis Software FD
Slide 16: Focus of Initial Commercial Launch: Direct Patient Pay
16 Focus of Initial Commercial Launch: Direct Patient Pay • Establish HeartBeam as first personal, cable - free 12L ECG • Create a focused direct sales and marketing operation in US • Prove concept in select geographic markets, then expand • Establish premium pricing and subscription model • Focus o
Slide 17: Start direct, create playbook, prove concept
17 Start direct, create playbook, prove concept Concierge Additive to revenue; drive downstream treatments (stents, valves, pacemakers) Synergy with CAD Diagnostics companies: same customer and patient Broader Patient Pay Wearable identifies heart issue and prompts patient to use 12L ECG HeartBeam 1
Slide 18: Financial Discipline Cash Burn Aligned with Key Milestones
18 Financial Discipline Cash Burn Aligned with Key Milestones Strong foundation for execution Corporate Overview i. Approximate, as of January 3, 2025 ii. As of September 30, 2024; refer to the Form 10 - Q unaudited financial statements for the quarterly period ended September 30, 202 4 $5.8 Million
Slide 19: Operating cash burn aligned with key milestones
19 Operating cash burn of $3.3M in prior quarter i , aligned with key milestones Cash Burn Focused on financial discipline to deliver on goals while minimizing cash burn Financials Strong support from existing shareholders , committed to groundbreaking technologies Shareholder Support i. Calculated
Slide 20: Funding Next Wave of Milestones
20 Investment aligned with milestones Funding Next Wave of Milestones i. Refer to Slide 15 for HeartBeam 2025 Milestones. Commercial - readiness • Business development and partnerships • Initial build out of commercial team • Onboarding and customer service • Health economic studies and market acces
Slide 21: HeartBeam Leadership Team
21 BRANISLAV VAJDIC, PHD Founder & President KEN PERSEN Chief Technology Officer PETER FITZGERALD, MD, PHD Chief Medical Officer DEBORAH CASTILLO, PHD VP, Regulatory POOJA CHATERJEE VP, Clinical RICHA GUJARATI SVP, Product TIM CRUICKSHANK Chief Financial Officer HeartBeam Leadership Team LANCE MYERS
Slide 22: HeartBeam Scientific Advisory Board
22 PETER FITZGERALD, MD, PHD Chief Medical Officer C. MICHAEL GIBSON, MD SAB Chair CHARLES L. BROWN III, MD SAB Member TONY DAS, MD SAB Member CAMPBELL ROGERS, MD SAB Member NIRAJ VARMA, MD, PHD SAB Member ROBERT HARRINGTON, MD SAB Member HeartBeam Scientific Advisory Board Worldwide experts in card
Slide 23: Closing Summary
23 Closing Summary BREAKTHROUGH IN CARDIAC TECHNOLOGY • IP protected design: smallest, easiest - to - use and first cable - free 12 - lead ECG device • Potential for major advances over existing ambulatory ECG technology • Heart attack detection with patient • AI algorithms for early disease detecti
Slide 24: The Offering
24 Enables sufficient runway to reach next value - inflection milestones The Offering Price Per Share To Be Determined Offer Type Registered Public Offering* Security Straight Common Stock Offering Amount $10 MILLION * A copy of the registration statement can be found here: https://www.sec.gov/Archi